Experts are skeptical that Big Pharma companies will cut prices after President Donald Trump demands Most Favored Nation policies within 60 days.

On July 24, 2025, the PTO Acting Director Coke Morgan Stewart discretionarily denied Amgen’s IPR2025-00601 and IPR2025-00602 challenging ...

Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...

President Trump sent letters to 17 major pharmaceutical makers advising them that they had 60 days to lower their prices in ...

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

The FDA issued a complete response letter for Regeneron's lymphoma drug odronextamab. Elsewhere, Bristol Myers raised its guidance and analysts saw progress in Biogen’s turnaround.

The suprisingly weak hiring numbers led investors to step up their expectations for an interest rate cut in September.

The Health Resources and Services Administration has opened applications for a voluntary pilot program aimed at evaluating the 340B rebate model.  The 340B Program traditionally has offered up-front ...

Mayo Clinic has treated the first person in the U.S. using a novel radioactive medicine for advanced breast cancer as part of ...

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...